Blue Dart strengthens its specialised Temperature Controlled Logistics (TCL) solution in the nations fight against Covid-19

Currently offers strong Supply Chain Solutions for the Life Sciences, HealthCare and Clinical Trials Sector

Mumbai. Blue Dart, India’s leading express logistics service provider and part of the Deutsche Post DHL Group (DPDHL) with its commitment to help improve the supply chain and ensure timely medical provisions is ramping up its infrastructure with its pre-existing specialised Temperature Controlled Logistics (TCL) to combat the pandemic.

Blue Dart will further offer complete Supply Chain Solution for the Life Sciences and Clinical Trials Sector and reefer vehicles (cold chain) services to the vaccine sector to ensure seamless transport of shipments.

As the development of the COVID-19 vaccine leapfrogs across development phases, stringent temperature requirements (up to – 80°C) will be a critical factor for its transportation and warehousing at every stage. An efficient and specialized logistics network will be a prerequisite, to ensure safe and rapid delivery of billions of Covid-19 vaccine doses for mass immunization, and other temperature sensitive pharma products on a national & global scale.

Blue Dart has successfully tailored its existing Temperature Controlled Logistics solution to transport critical shipments such as vaccines, medical samples and more. The TCL teams work with three industry specific segments: Clinical Research Organization (CRO), Vaccine/Testing Kit manufactures and Active Pharma Ingredient for swift and safe delivery of shipments.

As per research on Blue Dart’s consumer feedback, conducted through Net Promoter Approach methodology, Blue Dart successfully scored a Net Promoter Score(NPS) of 100% for its TCL solutions, even higher than its other services which has an enviable NPS of 99.6%.

Mr. Ketan Kulkarni CMO & Head – Business Development, Blue Dart, said “The right partnerships are vital to secure critical medical supplies during health emergencies. We are actively working with various pharmaceutical organizations that are conducting clinical trials to produce a Covid-19 vaccine in India in their pre and post production journey.

As a part of the DPDHL Group, Blue Dart has the knowhow of the internal best practices in the life sciences and healthcare logistics business and is a part of a large global logistics network which allows us to use each of our sister Business Unit’s strength in providing the best solution to our customer.”

He further added, “A number of factors such as warehousing, packaging and transportation, regional distribution competence, consistent temperature management, requirement of special equipment and availability of trained personnel to handle the temperature-sensitive vaccines will come into play once the vaccine is developed.

With an agile response team overseeing the upscaling of our current capabilities, strong fleet of dedicated Boeing 757 aircrafts and robust infrastructure for our Temperature Controlled Logistics solutions, we are capable and prepared to meet any immediate large-scale demand.”

A look into our process flow-chart for Temperature Controlled Logistics

Blue Dart has continuously worked with the medical equipment and pharmaceuticals sector to maintain the supply chain and deliver critical shipment and essential supplies including Covid vaccine samples, temperature-controlled movement of COVID-19 testing kits, ventilators, PPE, testing kits, reagents, enzymes, respirators, surgical masks, goggles and gloves amongst other critical material. The company’s six Boeing 757 freighters ensure the ease in ramping up operations swiftly to handle large scale shipments.

As an express logistics service provider for the country, Blue Dart caters to over 35,000 locations. This ensures that operations in every state across India are covered through its network. With its access to a global shipping network, data driven transparency and insights, local knowledge and access and resilience in the face of a crisis, Blue Dart is armed to be the preferred partner of large and medium scale pharmaceutical and research companies.